CV, VTE Risk Not Seen in Derm Studies of JAK Inhibitors CV, VTE Risk Not Seen in Derm Studies of JAK Inhibitors
' There remains a knowledge gap regarding the risk of JAK inhibitor use and VTE and/or MACE in the dermatologic population, ' the study authors wrote.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 1, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
FDA Approves First Ustekinumab Biosimilar FDA Approves First Ustekinumab Biosimilar
The drug has also been granted an interchangeability designation and has been approved for six indications.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 1, 2023 Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news
Study Finds Ruxolitinib Effective, Safe for Children With AD Study Finds Ruxolitinib Effective, Safe for Children With AD
There were no significant safety signals in the younger pediatric population, and ' no treatment-emergent adverse events suggestive of systemic JAK inhibition, ' Dr Lawrence Eichenfield said.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 1, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
FDA Approves Secukinumab for Adults With HS FDA Approves Secukinumab for Adults With HS
This marks the second FDA-approved agent for the condition, and the first IL-17A inhibitor.FDA Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 1, 2023 Category: Allergy & Immunology Tags: Dermatology News Alert Source Type: news
FDA Approves Abatacept for Pediatric Patients With Psoriatic Arthritis FDA Approves Abatacept for Pediatric Patients With Psoriatic Arthritis
As many as 5% of pediatric patients with juvenile idiopathic arthritis are estimated to have juvenile PsA.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 31, 2023 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
RSV More Common in IBD RSV More Common in IBD
All patients with IBD, regardless of age, may be at increased risk for contracting a respiratory syncytial virus (RSV) infection and, as such, may benefit from receiving an RSV vaccine.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 31, 2023 Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news
Trial Shows Precision Medicine in RA'Remains Elusive'Trial Shows Precision Medicine in RA'Remains Elusive '
Histologic analysis did not sufficiently predict treatment response to certain medications, but methods involving gene expression and transcriptome analysis may be more promising.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 31, 2023 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
His Rare Disease's Cure Was Sitting on the Pharmacy Shelf His Rare Disease's Cure Was Sitting on the Pharmacy Shelf
He ' s alive thanks to a repurposed drug. Now his dream is to find cures for millions of people from among drugs we already have.Medscape (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 31, 2023 Category: Allergy & Immunology Tags: Internal Medicine Expert Interview Source Type: news
Dupilumab-Associated Lymphoid Reactions Require Caution Dupilumab-Associated Lymphoid Reactions Require Caution
Retrospective study identifies potential for misdiagnosed mycosis fungoides and for dupilumab to fuel cutaneous lymphoid reactions that mimic mycosis fungoides in patients with atopic dermatitis.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 30, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Marijuana: We Must Still Warn Users of Risks Marijuana: We Must Still Warn Users of Risks
Art Caplan discusses the changing federal policies on marijuana.Medscape Business of Medicine (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 30, 2023 Category: Allergy & Immunology Tags: Family Medicine/Primary Care Commentary Source Type: news
West Nile Virus and Other Arboviral Diseases -- U.S., 2021 West Nile Virus and Other Arboviral Diseases -- U.S., 2021
A new report sheds light on the nationwide rates of West Nile virus and other arboviral infections in 2021.Morbidity & Mortality Weekly Report (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 30, 2023 Category: Allergy & Immunology Tags: Public Health & Prevention Journal Article Source Type: news
Dupilumab Promising for Children Aged 1-11 With EoE Dupilumab Promising for Children Aged 1-11 With EoE
New evidence supports the safety and efficacy of dupilumab for children aged 1-11 years with eosinophilic esophagitis.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 27, 2023 Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news
Dupilumab Promising for Children Up to 12 Years Old With EoE Dupilumab Promising for Children Up to 12 Years Old With EoE
New evidence supports the safety and efficacy of dupilumab for children aged 1-12 years with eosinophilic esophagitis.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 26, 2023 Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news
Phenotype-Targeted Treatment Sought for Psoriatic Disease Phenotype-Targeted Treatment Sought for Psoriatic Disease
Researchers described ongoing work to"understand the discrete and overlapping endotypes that underlie the phenotypes" of psoriatic disease and to develop a diagnostic test for psoriatic arthritis.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 26, 2023 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
Subcutaneous Ocrelizumab, Ofatumumab'Reassuring' in MS Subcutaneous Ocrelizumab, Ofatumumab'Reassuring' in MS
Anti-CD20 antibody therapy can be effectively and safely administered subcutaneously to patients with MS, even when switching from a prior treatment, two clinical trials suggest.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 25, 2023 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
